20 November 2006

Dear Consultees and Commentators

Health Technology Appraisal

Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

As you are aware, the Appraisal Committee met to consider this appraisal on Wednesday 1 November 2006.

Consultees and commentators to the technology appraisal for ‘primary prevention’ were informed in a separate letter of the Institute’s decision to discuss the final recommendations of the Appraisal Committee with the Guideline Development Group (GDG) and as a result postpone the finalisation of the Final Appraisal Determination to the first meeting of the Appraisal Committee in 2007 which is planned for February 7.

As a consequence of the large amount of comments received in the consultation on the Appraisal Consultation Document for ‘primary prevention’ the Appraisal Committee did not discuss the ‘secondary prevention’ technology appraisal on 1 November 2006. The review of the appraisal of the technologies for ‘secondary prevention’ is thus postponed to the meeting of 7 February 2007.

I know that you will be disappointed in this further extension of the timeline for this appraisal, but I hope you agree that the way forward outlined above will enable the development of a complete set of guidance which in the end will be more appropriate for the NHS.

Thank you again for your input into this appraisal; if you have any questions or queries, please contact Mr Reetan Patel, Technology Appraisal Project Manager (email: reetan.patel@nice.org.uk or ☎️ 020 7067 5946).

Yours sincerely

Dr Carole Longson
Director Centre for Health Technology Evaluation